This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

BIOLASE, Inc. Sued By Investor

Stocks in this article: BIOL

SAN DIEGO and IRVINE, Calif., Aug. 27, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that an investor of BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE") has filed a complaint in the U.S. District Court for the Central District of California.  The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between January 7, 2013 and August 12, 2013 (the "Class Period").  BIOLASE develops, manufactures, and markets lasers in dentistry and medicine.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

BIOLASE Accused of Making False and Misleading Statements

According to the complaint, certain BIOLASE officers and directors made false and/or misleading statements and/or failed to disclose information regarding the company's business, operations, and prospects.  Specifically, the complaint alleges that, throughout the Class Period, the company and certain of its officers and directors misrepresented and failed to disclose that: (i) contrary to claims by the company that its dental lasers were "becoming the standard of care" in the industry, BIOLASE's lasers were in use in only 5% of dental offices and disfavored by many dentists because of their high cost; (ii) the company's attempt to convert to a direct sales model in the United States was failing because of the high cost of the dental lasers; (iii) BIOLASE was financially impaired by its high debt burden and the terms of its lines of credit with Comerica Bank; and (iv) BIOLASE failed to generate cash from operations and was in default of its lines of credit with Comerica Bank.  As a result of these false and misleading statements and omissions, BIOLASE shares traded at artificially inflated prices during the Class Period.

BIOLASE Stock Price Drops on News of Revenue and Earnings Misses

On August 7, 2013, according to the complaint, BIOLASE announced its financial results for its second quarter 2013, reporting revenue of $14.2 million and a $.06 per share loss.  Both revenue and earnings numbers were significantly below the $15.69 million revenue and $.04 per share loss BIOLASE had led the market to expect.  Then, on August 13, 2013, BIOLASE issued a press release announcing that the company had violated the terms of its covenants with Comerica Bank.  On this news, BIOLASE shares fell to $1.81 on August 13, 2013, down nearly 80% from a Class Period high of $6.05 reached on April 29, 2013.

If you invested in BIOLASE and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/biolase-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs